Condition: HER2-Positive Solid Tumor · Sponsor: Yuhan Corporation
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
This description comes directly from the study's public registry record.
Clinical Operation Team 1 · +82-2-828-0065 · clinicaltrials@yuhan.co.kr
Heayeon Yoo · +82-2-828-0065 · hy1221@yuhan.co.kr
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Vanderbilt Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| Southern Oncology Clinical Research Unit | Adelaide, Australia | Terminated |
| Austin Health | Melbourne, Australia | Withdrawn |
| Breast Cancer Research Centre - WA | Perth, Australia | Withdrawn |
| Blacktown Hospital | Sydney, Australia | Recruiting |
| CHA Bundang Medical Center | Seongnam-si, Gyeonggi-do, South Korea | Recruiting |
| Catholic University of Korea St. Vincent's Hospital | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Ajou University Hospital | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Gyeongsang National University Hospital | Jinju, Gyeongsangnam-do, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, North Chungcheong, South Korea | Recruiting |
| Gachon Gil University Medical Center | Incheon, South Korea | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05523947